Open Access

RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer

  • Authors:
    • Hiroaki Ono
    • Yoshiki Murase
    • Hironari Yamashita
    • Tomotaka Kato
    • Daisuke Asano
    • Yoshiya Ishikawa
    • Shuichi Watanabe
    • Hiroki Ueda
    • Keiichi Akahoshi
    • Kosuke Ogawa
    • Atsushi Kudo
    • Yoshimitsu Akiyama
    • Shinji Tanaka
    • Minoru Tanabe
  • View Affiliations

  • Published online on: March 2, 2023     https://doi.org/10.3892/ijo.2023.5499
  • Article Number: 51
  • Copyright: © Ono et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The invasiveness of pancreatic cancer and its resistance to anticancer drugs define its malignant potential, and are considered to affect the peritumoral microenvironment. Cancer cells with resistance to gemcitabine exposed to external signals induced by anticancer drugs may enhance their malignant transformation. Ribonucleotide reductase large subunit M1 (RRM1), an enzyme in the DNA synthesis pathway, is upregulated during gemcitabine resistance, and its expression is associated with worse prognosis for pancreatic cancer. However, the biological function of RRM1 is unclear. In the present study, it was demonstrated that histone acetylation is involved in the regulatory mechanism related to the acquisition of gemcitabine resistance and subsequent RRM1 upregulation. The current in vitro study indicated that RRM1 expression is critical for the migratory and invasive potential of pancreatic cancer cells. Furthermore, a comprehensive RNA sequencing analysis showed that activated RRM1 induced marked changes in the expression levels of extracellular matrix‑related genes, including N‑cadherin, tenascin‑C and COL11A. RRM1 activation also promoted extracellular matrix remodeling and mesenchymal features, which enhanced the migratory invasiveness and malignant potential of pancreatic cancer cells. The present results demonstrated that RRM1 has a critical role in the biological gene program that regulates the extracellular matrix, which promotes the aggressive malignant phenotype of pancreatic cancer.
View Figures
View References

Related Articles

Journal Cover

April-2023
Volume 62 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ono H, Murase Y, Yamashita H, Kato T, Asano D, Ishikawa Y, Watanabe S, Ueda H, Akahoshi K, Ogawa K, Ogawa K, et al: RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer. Int J Oncol 62: 51, 2023.
APA
Ono, H., Murase, Y., Yamashita, H., Kato, T., Asano, D., Ishikawa, Y. ... Tanabe, M. (2023). RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer. International Journal of Oncology, 62, 51. https://doi.org/10.3892/ijo.2023.5499
MLA
Ono, H., Murase, Y., Yamashita, H., Kato, T., Asano, D., Ishikawa, Y., Watanabe, S., Ueda, H., Akahoshi, K., Ogawa, K., Kudo, A., Akiyama, Y., Tanaka, S., Tanabe, M."RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer". International Journal of Oncology 62.4 (2023): 51.
Chicago
Ono, H., Murase, Y., Yamashita, H., Kato, T., Asano, D., Ishikawa, Y., Watanabe, S., Ueda, H., Akahoshi, K., Ogawa, K., Kudo, A., Akiyama, Y., Tanaka, S., Tanabe, M."RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer". International Journal of Oncology 62, no. 4 (2023): 51. https://doi.org/10.3892/ijo.2023.5499